Fidelity Investments’s Mineralys Therapeutics MLYS Stock Holding History
Bought
Maintained
Sold
Other funds holding MLYS
Fidelity Investments's MLYS Position: Q3 2026 in Review
Fidelity Investments increased its Mineralys Therapeutics (MLYS) stake by 4.5% in Q3 2026, buying an estimated $5.48M and bringing the position to 4,713,195 shares worth $118M. The position accounts for 0.01% of the portfolio, ranked #1148.
Fidelity Investments first reported a position in MLYS in Q1 2023 and has held it in 15 quarters since. The position peaked at $184M in Q4 2025. 219 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.
- Fidelity Investments held 4,713,195 shares of Mineralys Therapeutics worth $118M as of Q3 2026.
- Fidelity Investments bought 201,506 Mineralys Therapeutics shares in Q3 2026, an estimated $5.48M.
- Mineralys Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q3 2026, its #1148 holding.
- Fidelity Investments first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 15 quarters since.
- Fidelity Investments's Mineralys Therapeutics position peaked at $184M in Q4 2025.
- 219 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.
Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.